Abinader E G, Shahar J
Cardiology. 1983;70(1):37-40. doi: 10.1159/000173567.
Episodes of ventricular tachycardia of the 'torsade de pointes' (VTTP) types provoked by prenylamine were observed in 7 patients: 5 females and 2 males. They all received prenylamine in a dose of 120-180 mg daily for anginal pains. Syncope or syncopal equivalents occurred in all 7 patients. Q-T intervals ranged from 0.52 to 0.64 s. Review of the literature revealed 11 patients with prenylamine-induced VTTP, of whom 8 were females. The female preponderance (72.2%), hitherto not commented upon in the literature, is highlighted. Prenylamine-indiced VTTP may appear late after initiation of therapy, consequently clinical and ECG long-term follow-up is mandatory. The drug should promptly be discontinued in symptomatic patients, and particularly in females showing prolonged Q-T.
7例患者出现了由普尼拉明诱发的“尖端扭转型”室性心动过速（VTTP）发作，其中5例女性，2例男性。他们均因心绞痛每日服用120 - 180毫克普尼拉明。所有7例患者均出现晕厥或晕厥样症状。Q-T间期为0.52至0.64秒。文献回顾发现11例普尼拉明诱发的VTTP患者，其中8例为女性。突出了女性占优势（72.2%）这一此前文献未提及的情况。普尼拉明诱发的VTTP可能在治疗开始后较晚出现，因此临床和心电图长期随访是必要的。有症状的患者，尤其是Q-T延长的女性患者，应立即停药。
